Caltius Structured Capital Closes Junior Capital Investment in Musculoskeletal Clinical Regulatory Advisers (“MCRA”)
December 12, 2017
Los Angeles, CA, December 2017 – Caltius Structured Capital announced it closed a junior capital investment in Musculoskeletal Clinical Regulatory Advisers, LLC (“MCRA”; mcra.com). Washington, DC-based MCRA will use the capital infusion to accelerate its successful growth strategy.
Founded in 2004, MCRA is a leading adviser and clinical research organization serving the neuro-musculoskeletal and medical device industries. MCRA’s unique value lies in its industry experience together with its successful integration of five business value creators: regulatory, reimbursement, clinical research, healthcare compliance and quality assurance. MCRA serves nearly 500 clients globally from its offices in Washington, DC, Manchester, Conn., and New York, N.Y.
“We are very excited to be partnering with MCRA to help management continue the company’s proven growth strategy,” noted Alisa Frederick, managing director of Caltius Structured Capital. “MCRA’s holistic approach to solving clients’ critical and complex issues has earned the company a market-leading position in the regulatory and clinical consulting space. We were extremely impressed by the quality of MCRA’s management team throughout our due diligence process, and are confident about MCRA’s bright future.“
“It has been a pleasure getting to know the Caltius team and we are excited about our opportunities with their well-structured junior capital investment,” noted David Lown, General Manager of MCRA. “The right capital partner is very important to us, and Caltius quickly demonstrated their extensive relevant experience investing growth capital in companies like MCRA.”